Abstract
α-Synuclein is a major component of Lewy bodies in Parkinsons disease and is found associated with several other forms of dementia. As with other neurodegenerative diseases, the ability of α-synuclein to aggregate and form fibrillar deposits seems central to its pathology. We have defined a sequence within the NAC region of α-synuclein that is necessary for aggregation. Exploitation of chemically modified analogues of this peptide may produce inhibitors of aggregation.
Keywords: synuclein, amyloid, aggregation, parkinsons disease
Protein & Peptide Letters
Title: α-Synuclein Aggregation
Volume: 11 Issue: 3
Author(s): Angela M. Bodles and G. Brent Irvine
Affiliation:
Keywords: synuclein, amyloid, aggregation, parkinsons disease
Abstract: α-Synuclein is a major component of Lewy bodies in Parkinsons disease and is found associated with several other forms of dementia. As with other neurodegenerative diseases, the ability of α-synuclein to aggregate and form fibrillar deposits seems central to its pathology. We have defined a sequence within the NAC region of α-synuclein that is necessary for aggregation. Exploitation of chemically modified analogues of this peptide may produce inhibitors of aggregation.
Export Options
About this article
Cite this article as:
Bodles M. Angela and Irvine Brent G., α-Synuclein Aggregation, Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407084
DOI https://dx.doi.org/10.2174/0929866043407084 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research The Role of Iron Toxicity in Oxidative Stress-induced Cellular Degeneration in Down Syndrome: Protective Effects of Phenolic Antioxidants
Current Nutrition & Food Science Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Coping with Stress During Aging: The Importance of a Resilient Brain
Current Neuropharmacology Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Multiple Species Metabolism of PHA-568487, A Selective α7 Nicotinic Acetylcholine Receptor Agonist
Drug Metabolism Letters Consciousness, Functional Networks and Delirium Screening
Current Aging Science Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
Current Alzheimer Research Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Current Alzheimer Research Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology Acute Cellular Oxygen Sensing in the Heart - A Role for Mitochondria?
Vascular Disease Prevention (Discontinued) Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research Depression and Anxiety Levels Increase Chronic Musculoskeletal Pain in Patients with Alzheimer's Disease
Current Alzheimer Research The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Current Alzheimer Research Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence
Protein & Peptide Letters